Sprint Bioscience AB (SPRINT) - Total Liabilities

Latest as of March 2026: Skr12.69 Million SEK ≈ $1.37 Million USD

Based on the latest financial reports, Sprint Bioscience AB (SPRINT) has total liabilities worth Skr12.69 Million SEK (≈ $1.37 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Sprint Bioscience AB - Total Liabilities Trend (2011–2025)

This chart illustrates how Sprint Bioscience AB's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Sprint Bioscience AB to evaluate short-term liquidity relative to the company's equity base.

Sprint Bioscience AB Competitors by Total Liabilities

The table below lists competitors of Sprint Bioscience AB ranked by their total liabilities.

Company	Country	Total Liabilities
SuNam Co. Ltd KQ:294630	Korea	₩6.16 Billion
Bintang Samudera Mandiri Lines Tbk PT JK:BSML	Indonesia	Rp96.90 Billion
360 Capital Group AU:TGP	Australia	AU$80.96 Million
Orient Ceratech Limited NSE:ORIENTCER	India	Rs1.20 Billion
York Timber Holdings Ltd JSE:YRK	South Africa	ZAC1.86 Billion
180 Degree Capital Corp NASDAQ:TURN	USA	$2.85 Million
Beammwave AB B ST:BEAMMW-B	Sweden	Skr6.25 Million
European Metals Holdings Ltd AU:EMH	Australia	AU$2.94 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Sprint Bioscience AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sprint Bioscience AB market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	9.10	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.12	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.11	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sprint Bioscience AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sprint Bioscience AB (2011–2025)

The table below shows the annual total liabilities of Sprint Bioscience AB from 2011 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr17.48 Million ≈ $1.88 Million	-46.67%
2024-12-31	Skr32.78 Million ≈ $3.53 Million	-5.26%
2023-12-31	Skr34.60 Million ≈ $3.72 Million	+274.73%
2022-12-31	Skr9.23 Million ≈ $993.73K	+6.35%
2021-12-31	Skr8.68 Million ≈ $934.43K	-64.20%
2020-12-31	Skr24.25 Million ≈ $2.61 Million	+194.82%
2019-12-31	Skr8.23 Million ≈ $885.36K	-62.68%
2018-12-31	Skr22.05 Million ≈ $2.37 Million	+198.09%
2017-12-31	Skr7.40 Million ≈ $795.93K	-64.83%
2016-12-31	Skr21.03 Million ≈ $2.26 Million	-18.54%
2015-12-31	Skr25.81 Million ≈ $2.78 Million	+434.79%
2014-12-31	Skr4.83 Million ≈ $519.44K	+17.47%
2013-12-31	Skr4.11 Million ≈ $442.19K	+28.24%
2012-12-31	Skr3.20 Million ≈ $344.81K	+329.45%
2011-12-31	Skr746.09K ≈ $80.29K	--

About Sprint Bioscience AB

ST:SPRINT Sweden Biotechnology

Market Cap

$49.62 Million

Skr461.10 Million SEK

Market Cap Rank

#21990 Global

#408 in Sweden

Share Price

Skr4.37

Change (1 day)

+1.16%

52-Week Range

Skr0.45 - Skr4.37

All Time High

Skr47.75